HI-Bio: pairing immune cell-targeting approach with deal to drive clinical work

Two in-licensed programs from MorphoSys will be the first test cases for HI-Bio’s belief that it can develop more precisely targeted medicines for patients with immune-mediated diseases driven by cellular dysfunction.

Emerging from stealth mode on Tuesday with $120 million, Human Immunology Biosciences Inc. — informally, HI-Bio — was already aiming to target disease-driving dysfunction among immune cell types such as plasma cells, neutrophils and mast cells when the opportunity arose to obtain rights to two programs from MorphoSys AG (Xetra:MOR; NASDAQ:MOR), CEO Travis Murdoch told BioCentury...